Brexit Will Be Bad For Pharma
In this
nice piece of article on Forbes, http://www.forbes.com/sites/stephenbrozak/2016/06/25/brexit-will-be-bad-for-pharma/#398890a57ab3 the
author highlights the impact of Britain's potential exit from the European
Union on the pharmaceutical industry.
Summary:
1. Big Pharma’s balance
sheets just took a hit:
Between
the UK and the EU, most large pharmaceuticals have more than 20% of their sales
in the region; as a result, these companies will be working the numbers this
weekend to see how their performance will be affected by Brexit and the ensuing
financial chaos.
2. The healthcare capital markets have now come
to a screeching halt:
With a
decompensating banking system, the UK’s financial chaos will certainly have a
domino effect across the rest of the continent. Management teams will be
distracted, layoffs will certainly ensue and, once that happens, meaningful
R&D will slow down as workers begin to worry about their jobs.
3. Even the EMA is a question mark:
The
European Medicines Agency (EMA) is the pharmaceutical regulatory agency for
Europe. Right now, the word is: “Don’t panic. No changes soon.” Nice to know,
since EMA headquarters is Canary Wharf, London.
4. The downsides of inversions:
As EU
cohesion and European financial instability become issues, tax laws as well as
trading relationships are in play.
Remember: Pharmaceutical and medical device companies aren’t just
service providers. They are among the largest industries in the world. They
require stability. And suddenly, we don’t have it.
Comments
Post a Comment